Dyamed’s subgroup success doesn’t translate to Phase III in Type I diabetes, Kodiak data and more 

The more than 20 clinical readouts from publicly traded biotechs over the past week led to major gains and losses for some of their stocks, including moves of at least 50% from the week’s biggest advancers and decliners.

Diamyd Medical AB (SSE:DMYD B) lost 89% of its value Monday after a readout on Friday for the company’s retogatein vaccine, designed to produce immune tolerance to the GAD65 autoantigen, failed to produce a treatment effect on C-peptide in patients with Type I diabetes with HLA DR3-DQ2 haplotype in the Phase III DIAGNODE-3 trial...